Abstract
The deleted in liver cancer (DLC-1) gene at chromosome 8p21–22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth. Given the high frequency of deletion involving region 8p21–22 in human non-small cell lung carcinoma (NSCLC), we examined alterations of DLC-1 in a series of primary tumors and tumor cell lines and tested effects of DLC-1 on tumor cell growth. A significant decrease or absence of the DLC-1 mRNA expression was found in 95% of primary NSCLC (20/21) and 58% of NSCLC cell lines (11/19). Transcriptional silencing of DLC-1 was primarily associated with aberrant DNA methylation, rather than genomic deletion as 5-aza-2′-deoxycytidine induced reactivation of DLC-1 expression in 82% (9/11) NSCLC cell lines showing downregulated DLC-1. It was further evidenced by an aberrant DLC-1 promoter methylation pattern, which was detected by Southern blotting in 73% (8/11) of NSCLC cell lines with downregulation of the gene. The transfer of DLC-1 into three DLC-1 negative cell lines caused a significant inhibition in cell proliferation and/or a decrease in colony formation. Furthermore, stable transfer of DLC-1 abolished tumorigenicity in nude mice of two cell lines, suggesting that DLC-1 plays a role in NSCLC by acting as a bona fide new tumor suppressor gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arbieva ZH, Banerjee K, Kim SY, Edassery SL, Maniatis VS, Horrigan SK and Westbrook CA . (2000). Genome Res., 10, 244–257.
Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA and Crowell RE . (2002). Cancer Res., 62, 2370–2377.
Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, Bohle RM, Harbott J, Repp R, Jaeger U, Viehmann S, Henn T, Korth P, Scharr D and Lampert F . (2000). Proc. Natl. Acad. Sci. USA, 97, 9168–9173.
Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY and Ng IO . (2003). J. Biol. Chem., 278, 10824–10830.
Doll R and Peto R . (1981). J. Natl. Cancer Inst., 66, 1191–1308.
Fritz G, Just I and Kaina B . (1999). Int. J. Cancer, 81, 682–687.
Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF and Minna JD . (2000). Cancer Res., 60, 4894–4906.
Homma Y and Emori Y . (1995). EMBO J., 14, 286–291.
Jemal A, Chu KC and Tarone RE . (2001). J. Natl. Cancer Inst., 93, 277–283.
Khosravi-Far R, Solski PA, Clark GJ, Kinch MS and Der CJ . (1995). Mol. Cell. Biol., 15, 6443–6453.
Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim NK, Jung M and Bang YJ . (2003). Oncogene, 22, 3943–3951.
Knudson AG . (1993). Proc. Natl. Acad. Sci. USA, 90, 10914–10921.
Kurimoto F, Gemma A, Hosoya Y, Seike M, Takenaka K, Uematsu K, Yoshimura A, Shibuya M and Kudoh S . (2001). Int. J. Mol. Med., 8, 89–93.
Minna JD, Fong K, Zochbauer-Muller S and Gazdar AF . (2002). Cancer J., 8, S41–6.
Ng IO, Liang ZD, Cao L and Lee TK . (2000). Cancer Res., 60, 6581–6584.
Niklinski J, Niklinska W, Chyczewski L, Becker HD and Pluygers E . (2001). Eur. J. Cancer Prev., 10, 213–226.
Park SW, Durkin ME, Thorgeirsson SS and Popescu NC . (2003). Int. J. Oncol., 23, 133–137.
Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, Feder M, Jen J and Testa JR . (2001). Genes Chromosomes Cancer, 31, 282–287.
Plaumann M, Seitz S, Frege R, Estevez-Schwarz L and Scherneck S . (2003). J. Cancer Res. Clin. Oncol., 129, 349–354.
Qiu RG, Chen J, McCormick F and Symons M . (1995). Proc. Natl. Acad. Sci. USA, 92, 11781–11785.
Shopland DR . (1995). Environ. Health Perspect., 103, 131–142.
Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK and Mao L . (2002). Cancer Res., 62, 351–355.
Steenland K, Loomis D, Shy C and Simonsen N . (1996). Am. J. Ind. Med., 29, 474–490.
Tikoo A, Czekay S, Viars C, White S, Heath JK, Arden K and Maruta H . (2000). Gene, 257, 23–31.
Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM and Baffa R . (2001). Clin. Cancer Res., 7, 1546–1552.
Wilson PJ, McGlinn E, Marsh A, Evans T, Arnold J, Wright K, Biden K, Young J, Wainwright B, Wicking C and Chenevix-Trench G . (2000). Hum. Mutat., 15, 156–165.
Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD and Gazdar AF . (1999). Cancer Res., 59, 1973–1979.
Yin XL, Hui AB, Pang JC, Poon WS and Ng HK . (2002). Cancer Genet. Cytogenet., 134, 71–76.
Yuan BZ, Durkin ME and Popescu NC . (2003a). Cancer Genet. Cytogenet., 140, 113–117.
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC . (1998). Cancer Res., 58, 2196–2199.
Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS and Popescu NC . (2003b). Oncogene, 22, 445–450.
Zheng SL, Mychaleckyj JC, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Chang BL, von Kap-Herr C, Carpten JD, Pettenati M, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB and Xu J . (2003). Mutat. Res., 528, 45–53.
Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF and Minna JD . (2001). Cancer Res., 61, 3581–3585.
Zochbauer-Muller S, Minna JD and Gazdar AF . (2002). Oncologist, 7, 451–457.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yuan, BZ., Jefferson, A., Baldwin, K. et al. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 23, 1405–1411 (2004). https://doi.org/10.1038/sj.onc.1207291
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207291
Keywords
This article is cited by
-
Metastasis suppressor genes in clinical practice: are they druggable?
Cancer and Metastasis Reviews (2023)
-
Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer
Journal of Gastrointestinal Cancer (2022)
-
Evaluation of surface water quality indices and ecological risk assessment for heavy metals in scrap yard neighbourhood
SpringerPlus (2016)
-
DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer
Diagnostic Pathology (2016)
-
DLC1 expression is reduced in human cutaneous melanoma and correlates with patient survival
Modern Pathology (2014)